Smokers' drug granted fast-track status
The FDA has granted fast-track status to Champix (varenicline), Pfizer's experimental smoking-cessation treatment. The company says the drug helps smokers quit by reducing the severity of cravings and withdrawal symptoms. If the review process begins in January 2006 as expected, approval to begin marketing the product could be granted by July. If approved, the drug is expected to compete with Sanofi-Aventis' Acomplia (rimonabant), which was developed originally for obesity but has been found to be effective in aiding smoking cessation as well.
Q&A: Pharmacist-Led Diabetes Management Transforms Patient Care and Clinical Outcomes
June 28th 2025An ambulatory care pharmacist program in Washington State dramatically improved diabetes management by reducing A1c levels, increasing medication adherence, and providing comprehensive patient education.
